From: Altering phosphorylation in cancer through PP2A modifiers
Compounds | Cancer Types | Mechanisms | References |
---|---|---|---|
FTY720 | Acute myeloid leukemia | Impairs interaction of PP2Ac with SET | [81] |
Neuroblastoma | Inhibits proliferation, migration, and invasion | ||
Chronic myeloid leukemia | Impairs interaction of SET-PP2A, inhibits the BCR-ABL1 recruitment of JAK2, and activates GSK-3β | [137] | |
Colorectal cancer | Decreased phosphorylation of AKT1 and Erk1/2 | [79] | |
Breast cancer | Increases activation and expression of ERα and inhibits histone deacetylase | ||
Oral squamous cell carcinoma | Decreased phosphorylated GSK-3β | [25] | |
Multiple myeloma | Ferroptosis, autophagy, apoptosis, and ROS activation | ||
Ovarian cancer | Autophagy and non-apoptotic cell death | [88] | |
Gastric cancer | Increases PTEN and p53, decreases p-AKT1 and MDM2, induces G1 cell cycle arrest and apoptosis | [87] | |
Lung cancer | Decreases S1P-induced IL-6 and IL-8 and TNF-induced COX2, activation of PP2A-RIPK1-dependent necroptosis | ||
Hepatocellular carcinoma | ROS-dependent activation of PKCδ and caspase-3-dependent apoptosis | [139] | |
CM-1231 | Acute myeloid leukemia | Targets SET | [91] |
OSU-2S | Acute myeloid leukemia | Impairs interaction of SET and PP2Ac, c-Myc degradation and increased p21 | [90] |
Chronic lymphocytic leukemia | Nuclear translocation of SHP1S591 | [89] | |
OP449 | Acute myeloid leukemia | Antagonizes SET | |
Chronic myeloid leukemia | [140] | ||
Bortezomib | Triple negative breast cancer | Inhibits CIP2A, decreased p-AKT1 | |
Colorectal cancer | Â | Â | |
Ethoxysanguinarine (ESG) | Lung cancer | Inhibits CIP2A, decreased c-Myc and p-AKT1, apoptosis | [94] |
TD52 | Triple negative breast cancer | Inhibits CIP2A, interrupts ELK1 binding to CIP2A promoter, decreased p-AKT1 | [93] |
Hepatocellular carcinoma | [95] | ||
Arctigenin | Triple negative breast cancer | Inhibits CIP2A | [141] |
Celastrol | Gastric cancer | CIP2A degradation, increased apoptosis | [142] |
Niclosamide | Non-small cell lung cancer | Inhibits CIP2A, increased mitochondrial ROS | [143] |
Polyphyllin I | Prostate cancer | Inhibits CIP2A and ERK | [99] |
Lapatinib | Triple negative breast cancer | Inhibits CIP2A and p-AKT1 | [98] |